NeoGenomics Inc. priced an underwritten public offering of 9,800,000 common shares at $12.75 each.

The Fort Myers, Fla.-based operator of cancer-focused genetic testing laboratories expects to raise gross proceeds of about $125 million.

Underwriters have a 30-day option to buy up to 1,470,000 additional common shares at the offering price.

The company expects the offering to close on or about Aug. 14, subject to customary closing conditions.

Net proceeds will be used to grow NeoGenomics' business through potential acquisitions and investments. Funds may also go toward working capital and general corporate purposes.

William Blair and Leerink Partners are acting as joint book-running managers for the offering, with Craig-Hallum Capital Group, Stephens Inc., First Analysis Securities Corp., Janney Montgomery Scott and The Benchmark Co. LLC as co-managers.